Most know by now that Aimovig (erenumab) is our First CGRP Drug for Migraine and it wast just approved by the FDA
this week. Aimovig is a preventive treatment for migraines. Here is a “cheat sheet” of the most important Aimovig bulletpoints, followed by the top links with more information.
- WHEN? Aimovig is scheduled to be available to the public in less than a week.
- HOW? Aimovig is a self-injected subcutaneous medication to be dosed once a month. It blocks the activity of CGRP or calcitonin gene-related peptide, a molecule in the migraine pathway
- HOW MUCH? The cost will be $575 per injection (per month); or $6,900 per year. There is information on the Amgen website related to cost support here: https://www.aimovig.com/co-pay-and-support
- DOES IT WORK?In two separate studies of episodic migraine, patients on Aimovig reduced their monthly migraine days by 1-2 per month. In a study of chronic migraine, patients reduced their migraine days by 2.5 per month.
Go here for the official Aimovig Press Release: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm608120.htm
Go here for the latest PubMed link to the latest article on erenumab: https://www.ncbi.nlm.nih.gov/pubmed/29471679